Hikma Pharmaceuticals PLC closed 12.80% below its 52-week high of £23.60, which the company reached on February 13th.

Hikma Pharmaceuticals PLC HIK shares shed 2.70% to £20.16 Thursday, on what proved to be an all-around positive trading ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...

In a report released today, James Gordon from J.P. Morgan reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report). The ...

In a report released yesterday, Victoria Lambert from Berenberg Bank maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), ...

JPMorgan Chase & Co. restated their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report released on Friday morning, Marketbeat.com reports. Separately, Berenberg ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn) and operating profit up 67 per cent to $612m (£483m). Profit attributable ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...